Published in Hepatology on March 01, 2005
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2014) 3.38
Alterations of the human gut microbiome in liver cirrhosis. Nature (2014) 3.02
The microbiome and cancer. Nat Rev Cancer (2013) 2.86
Toll-like receptors as targets in chronic liver diseases. Gut (2009) 2.29
Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol (2012) 2.28
Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology (2010) 2.23
So depression is an inflammatory disease, but where does the inflammation come from? BMC Med (2013) 2.02
Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol (2012) 1.98
Probiotics and immunity. J Gastroenterol (2009) 1.79
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol (2011) 1.79
Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut (2015) 1.54
Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol (2006) 1.29
Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol (2010) 1.21
Diagnostic Accuracy of Ascites Fluid Gross Appearance in Detection of Spontaneous Bacterial Peritonitis. Emerg (Tehran) (2014) 1.18
Toll-like receptor 4 and hepatic fibrogenesis. Semin Liver Dis (2010) 1.13
The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int (2010) 1.12
Genetic diversity and virulence profiles of Escherichia coli isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. J Clin Microbiol (2010) 1.11
Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol (2012) 1.10
Analysis of monocyte chemotactic protein-1 gene polymorphism in patients with spontaneous bacterial peritonitis. World J Gastroenterol (2009) 1.05
Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog (2015) 1.03
Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoS One (2011) 1.02
Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim Biophys Acta (2012) 0.99
Diagnosis and management of bacterial infections in decompensated cirrhosis. World J Hepatol (2013) 0.99
The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev (2015) 0.99
Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci (2012) 0.98
Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study. Gut Liver (2009) 0.97
Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol (2014) 0.97
Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochenschr (2009) 0.96
Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol (2014) 0.95
Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol (2012) 0.95
Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterol (2010) 0.93
Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol (2014) 0.92
Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. Curr Microbiol (2012) 0.92
Risk factors of cellulitis in cirrhosis and antibiotic prophylaxis in preventing recurrence. Ann Gastroenterol (2014) 0.91
The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol (2012) 0.91
Beta-blockers in liver cirrhosis. Ann Gastroenterol (2014) 0.90
Gut microbiota-related complications in cirrhosis. World J Gastroenterol (2014) 0.90
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. Nutrients (2013) 0.89
Mesenteric microcirculatory dysfunctions and translocation of indigenous bacteria in a rat model of strangulated small bowel obstruction. Clinics (Sao Paulo) (2009) 0.89
Presence of anti-microbial antibodies in liver cirrhosis--a tell-tale sign of compromised immunity? PLoS One (2010) 0.89
Effect of honey on bacterial translocation and intestinal morphology in obstructive jaundice. World J Gastroenterol (2008) 0.89
HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway. PLoS One (2012) 0.88
The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection. Clin Exp Immunol (2011) 0.88
Nucleotide-Binding Oligomerization Domain-Containing Protein 2 Variants in Patients with Spontaneous Bacterial Peritonitis. Dig Dis Sci (2016) 0.88
Citrobacter peritoneal dialysis peritonitis: rare occurrence with poor outcomes. Int J Med Sci (2013) 0.87
Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. Crit Care (2011) 0.87
Acute-on-chronic liver failure: a review. Ther Clin Risk Manag (2014) 0.87
Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol (2012) 0.87
New determinants of prognosis in bacterial infections in cirrhosis. World J Gastroenterol (2014) 0.87
Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int (2014) 0.87
Salvianolate inhibits cytokine gene expression in small intestine of cirrhotic rats. World J Gastroenterol (2011) 0.86
C-reactive protein and bacterial infection in cirrhosis. Ann Gastroenterol (2014) 0.86
Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. World J Gastroenterol (2012) 0.85
Intestinal permeability in rats with CCl4-induced portal hypertension. World J Gastroenterol (2006) 0.85
The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS). BMC Gastroenterol (2011) 0.85
Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol (2015) 0.84
The effect of intestinal permeability and endotoxemia on the prognosis of acute pancreatitis. Gut Liver (2012) 0.84
Cirrhotic cardiomyopathy. World J Gastroenterol (2015) 0.84
Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol (2016) 0.83
Cirrhotic Multiorgan Syndrome. Dig Dis Sci (2015) 0.82
Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis. J Clin Immunol (2007) 0.82
Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis. PLoS One (2012) 0.81
Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system. PLoS One (2014) 0.81
Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. BMC Genomics (2014) 0.81
Effect of salvianolate on intestinal epithelium tight junction protein zonula occludens protein 1 in cirrhotic rats. World J Gastroenterol (2012) 0.80
Connecting the dots: could microbial translocation explain commonly reported symptoms in HIV disease? J Assoc Nurses AIDS Care (2014) 0.80
Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. Dig Dis Sci (2013) 0.80
Epidemiology and outcome of primary community-acquired bacteremia in adult patients. Eur J Clin Microbiol Infect Dis (2007) 0.80
Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. PLoS One (2013) 0.80
Liver cirrhosis as a real risk factor for necrotising fasciitis: a three-year population-based follow-up study. Singapore Med J (2014) 0.79
Protective Effect of the Total Saponins from Rosa laevigata Michx Fruit against Carbon Tetrachloride-Induced Liver Fibrosis in Rats. Nutrients (2015) 0.79
Propolis reduces bacterial translocation and intestinal villus atrophy in experimental obstructive jaundice. World J Gastroenterol (2007) 0.79
Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int (2008) 0.79
Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep (2016) 0.79
Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis. Gastroenterol Res Pract (2012) 0.78
Recipient's genetic R702W NOD2 variant is associated with an increased risk of bacterial infections after orthotopic liver transplantation. PLoS One (2013) 0.78
Bacterial translocation and endotoxemia after pringle maneuver in cirrhotic rats. Dig Dis Sci (2014) 0.78
Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. Dig Dis Sci (2017) 0.77
Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis. Eur J Nutr (2015) 0.77
Intestinal alkaline phosphatase inhibits the translocation of bacteria of gut-origin in mice with peritonitis: mechanism of action. PLoS One (2015) 0.77
Pringle maneuver deteriorates gut barrier dysfunction induced by extended-liver radiofrequency ablation. Dig Dis Sci (2010) 0.77
Patients with end-stage renal disease were at an increased risk of hospitalization for acute diverticulitis. Medicine (Baltimore) (2016) 0.77
Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol (2015) 0.77
Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study. World J Gastroenterol (2016) 0.77
Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia. World J Gastroenterol (2016) 0.77
Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar? Curr Drug Targets (2015) 0.77
A retrospective study of bacterial infections in cirrhosis. Maedica (Buchar) (2011) 0.77
Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis. World J Hepatol (2015) 0.77
Vascular stasis, intestinal hemorrhage, and heightened vascular permeability complicate acute portal hypertension in cd39-null mice. Am J Physiol Gastrointest Liver Physiol (2009) 0.76
Gut microbiome and liver disease. Transl Res (2016) 0.76
Systemic levels of human β-defensin 1 are elevated in patients with cirrhosis. Ann Gastroenterol (2016) 0.76
Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Aliment Pharmacol Ther (2016) 0.76
Oxymatrine improves intestinal epithelial barrier function involving NF-κB-mediated signaling pathway in CCl4-induced cirrhotic rats. PLoS One (2014) 0.76
Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol (2014) 0.76
Ascitic Fluid Calprotectin and Serum Procalcitonin as Accurate Diagnostic Markers for Spontaneous Bacterial Peritonitis. Gut Liver (2016) 0.75
PREVALENCE OF BACTERIAL RESISTANCE IN HOSPITALIZED CIRRHOTIC PATIENTS IN SOUTHERN BRAZIL: A NEW CHALLENGE. Rev Inst Med Trop Sao Paulo (2016) 0.75
The intestinal microbiome and surgical disease. Curr Probl Surg (2016) 0.75
The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med (2016) 0.75
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
Vascular disorders of the liver. Hepatology (2009) 5.38
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis (2008) 2.47
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
Recommendations for probiotic use--2008. J Clin Gastroenterol (2008) 1.76
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: a diagnostic accuracy study. Hepatology (2014) 1.60
Intensive care of the patient with cirrhosis. Hepatology (2011) 1.54
Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol (2005) 1.51
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl (2011) 1.44
Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol (2004) 1.43
Treatment of portal hypertension. World J Gastroenterol (2012) 1.39
Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol (2010) 1.36
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology (2013) 1.35
Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int (2012) 1.29
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology (2008) 1.24
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology (2008) 1.21
Patients' preferences for treatment of hepatitis C. Med Decis Making (2009) 1.20
Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology (2014) 1.16
High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol (2012) 1.15
Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol (2009) 1.14
Management of gastropathy and gastric vascular ectasia in portal hypertension. Clin Liver Dis (2010) 1.09
Prevention and treatment of infections in patients with cirrhosis. Best Pract Res Clin Gastroenterol (2007) 1.05
What do patients consider when making decisions about treatment for hepatitis C? Am J Med (2005) 1.03
The management of portal hypertensive gastropathy and gastric antral vascular ectasia. Dig Liver Dis (2010) 1.02
Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol (2009) 1.01
Patients' experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns (2005) 1.01
A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage. Hepatology (2008) 0.97
Multiple angiomyolipomata of the liver: a case report. Mod Pathol (2002) 0.97
Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology (2012) 0.93
Psychosocial issues in hepatitis C: a qualitative analysis. Psychosomatics (2009) 0.93
Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am (2010) 0.92
Classification of cirrhosis: the clinical use of HVPG measurements. Dis Markers (2011) 0.92
Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol (2013) 0.92
Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia. Hepatology (2013) 0.89
Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology (2014) 0.88
Liver involvement in hereditary hemorrhagic telangiectasia: CT and clinical findings do not correlate in symptomatic patients. AJR Am J Roentgenol (2006) 0.87
Serum Albumin Can Identify Patients With Compensated Cirrhosis With a Good Prognosis. J Clin Gastroenterol (2015) 0.87
Hepatic vascular malformations in hereditary hemorrhagic telangiectasia. Semin Liver Dis (2008) 0.86
Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence (2012) 0.86
Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology (2003) 0.85
Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology (2007) 0.84
Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis. Clin Gastroenterol Hepatol (2010) 0.84
Primary prophylaxis of variceal hemorrhage in children with portal hypertension: a framework for future research. J Pediatr Gastroenterol Nutr (2011) 0.84
Probiotics and liver disease. J Clin Gastroenterol (2008) 0.83
Decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhotics and healthy controls. J Clin Gastroenterol (2013) 0.82
Managing varices: drugs, bands, and shunts. Gastroenterol Clin North Am (2011) 0.81
Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: and the winner is... Hepatology (2009) 0.80
A commonsense approach to esophageal varices. Clin Liver Dis (2006) 0.79
Hepatic arteriolosclerosis: a small-vessel complication of diabetes and hypertension. Am J Surg Pathol (2015) 0.79
Spontaneous bacterial peritonitis. Rev Gastroenterol Mex (2005) 0.78
Non-hemorrhagic acute complications associated with cirrhosis and portal hypertension. Best Pract Res Clin Gastroenterol (2013) 0.78
Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? J Clin Gastroenterol (2016) 0.77
Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference? Gastroenterology (2002) 0.76
Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. Ultrasound Q (2016) 0.76
Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: in search of predictors of significant disease. Hepatology (2008) 0.75
Reply to: "Acute-on-chronic liver failure - its definition remains unclear". J Hepatol (2013) 0.75
The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol (2012) 0.75
Portal hypertension and hepatocellular carcinoma: prognosis and beyond. Clin Gastroenterol Hepatol (2006) 0.75
Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension. Curr Treat Options Gastroenterol (2007) 0.75
Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study. J Clin Gastroenterol (2016) 0.75
Editorial: Clostridium difficile infection: Yet another predictor of poor outcome in cirrhosis. Am J Gastroenterol (2010) 0.75
Reply to Risk Stratification in Acute Variceal Bleeding: Child-Pugh Versus Model for End-stage Liver Disease. J Clin Gastroenterol (2017) 0.75